Filgrastim: A Reappraisal of Pharmacoeconomic Considerations in the Prophylaxis and Treatment of Chemotherapy-Induced Neutropenia

PharmacoEconomics

Volumn 9, Issue 1, 1996, Pages 76-96

  Frampton, James E ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FEVER; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; NEUTROPENIA; PHARMACOECONOMICS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; STEM CELL;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 0030058739     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609010-00008     Document Type: Review

References (62)

1. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994 Nov; 48: 731-60
2. Jones-Grizzle AJ, Bootman JL. Pharmacoeconomics of genetically engineered drugs. PharmacoEconomics 1992; 1: 45-53
3. Faulds D, Lewis NJW, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF). Pharmacoeconomic considerations in chemotherapy-induced neutropenia. PharmacoEconomics 1992 Apr; 1: 231-49
4. Weber RJ. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Clin Ther 1993 Jan-Feb; 15: 180-91
5. Goa KL, Bryson HM. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its Pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant. PharmacoEconomics 1994 Jan; 5: 56-77
6. Glaspy J. Economic effect of myeloid growth factors on cancer treatment. Clin Immunother 1994 Sep; 2: 192-205
7. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. PharmacoEconomics 1994 Sep;6: 233-9
8. Montero MC, Valdivia ML, Carvajal E. et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 1994 Aug 5; 16: 187-92
9. Antoñanzas F, Rovira J, Garuz R. Economic evaluation of prophylaxis with the recombinant stimulating factor of granulopoiesis [in Spanish]. Med Clin 1992 Nov 28: 99: 685-9
10. Sagmeister M, Horisberger B, Gessner U, et al. Assessment of the costs of side effects in cancer chemotherapy: method and result of a multinational study. In: Chytil MK, Duru G, Eimeren W, et al., editors. Healthcare. Prague: Omnipress Publishing, 1992: 758-61
11. Pekurinen M, Rissanen P. Economic aspects of treating neutropenic event: the Finnish case study. Kuopio: University of Kuopio, 1991
12. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Clin Infect Dis 1994 Feb; 18 Suppl. 2: 189-96
13. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1992; 29a: 319-24
14. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-6
15. American Society of Clinical Oncology. American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 1994; 12: 2471-508
16. Blaise D, Vernant JP, Fiere D, et al. A randomised controlled multicenter trial of recombinant human granulocyte colony stimulating factor (filgrastim) in patients treated by bone marrow transplantation (BMT) with total body irradiation (TBI) for acute lymphoblastic leukaemia (ALL) [abstract no. 248a]. Blood 1992; 80: 982
17. Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995 Feb; 15: 261-6
18. Kennedy MJ, Davis J, Passos-Coelho J, et al. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res 1993; 53: 5424-8
19. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-4
20. Teoh GKH, Tan PHC, Goh YT. Granulocyte colony stimulating factor significantly influences neutrophil recovery and duration of hospitalisation in bone marrow transplantation. Ann Acad Med Singapore 1994 Nov; 23: 823-7
21. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology Huntingt 1993 Oct; 7: 67-78
22. Hénon PR. Peripheral blood stem cell transplantations: past, present and future. Stem Cells 1993; 11: 154-72
23. Faucher C, le Corroller AG, Biaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994 Dec; 14: 895-901
24. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4
25. Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-19
26. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer A 1994 Nov. 30A: 1631-5
27. Russell NH, Pacey S. Economic evaluation of peripheral blood stem cell transplantation for lymphoma [letter]. Lancet 1992 Nov 21; 340: 1290
28. Lawless GD. Cost-effectiveness of autologous bone marrow transplation. Am J Health Syst Pharm 1995 Oct; 52 Suppl. 4: S11-4
29. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994 Oct 1; 121: 492-501
30. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by ad ministration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803-8
31. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer A 1993 Dec; 29A Suppl. 7: 23-30
32. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy (see comments). J Natl Cancer Inst 1993 Mar 17; 85: 488-93
33. Watkins-Riedel T, Greiner P, Mikulits R, et al. Cost-benefit analysis as an efficacious pharmacoeconomic method of evaluating potential savings from G-CSF therapy: a standardized comparison of incremental costs of cytotoxic chemotherapy-induced episodes of febrile neutropenia (FNE) in non-hematologic patients versus FNE-free treatment costs in Austria for 1993, demonstrated by aggressive poly-chemotherapy (high-dose CT) regimen of small-cell lung cancer in patients with or without adjunctive application of recombinant methionyl human G-CSF (Neupogen) during the first CT-cycle [abstract]. Int J Clin Pharmacol Ther 1994 Mar; 32: 158
34. Peroutka JA, Mutnick AH. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy. Formulary 1995 Jul; 30: 394-404
35. Riikonen P, Rahiala J, Salonvaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer Stem Cells 1995; 13: 289-94
36. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl. 2: 127-32
37. Tirelli U, Vaccher E. Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF) (letter). Eur J Cancer 1994; 30A: 1589-90
38. Tirelli U, Errante D, Tavio P, et al. Treatment of HIV-related non-Hodgkin's lymphoma (NHL) with chemotherapy (CT) and G-CSF: reduction in the days of hospitalization and toxicity with concomitant overall reduction in the cost [Abstract]. Proc Am Soc Clin Oncol 1993; 12: 53
39. Pekurinen M, Rissanen P. A tentative economic evaluation of granulocyte-colony stimulating factor in treatment ot small cell lung cancer in Finland [abstract]. Post Market Surveill 1992 Aug; 6: 53
40. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994 Jun; 12: 1245-50
41. Vey N, Molnar S, Faucher C, et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994 Nov; 14: 779-82
42. Clark RE, Shlebak AA, Creagh MD. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma 1994 Dec; 16: 141-6
43. Khwaja A, Mills W, Leveridge K, et al. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 1993 Jun; 11: 479-82
44. Peripheral blood progenitor cell transplantation with G-CSF more cost effective. FDC Rep Pink Sheet 1995 June 5; 57: T&G 11-12
45. Smith TJ, Hillner BE, Yanovich S, et al. Cost analysis of peripheral blood progenitor cell (PBPC) or autologous bone marrow (ABM) transplant in relapsed Hodgkin diasese (HD) and non-Hodgkin lymphoma (NHL). Proc Am Soc Clin Oncol 1995 Mar; 14
46. Uyl-de Groot CA, Ossenkoppele GJ, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilised by G-CSF (filgrastirn) following high dose melphalan as compared with conventional therapy in multiple myeloma [abstract]. Br J Haematol 1994; 87 Suppl. 1: 108
47. Mateos RJ, Gonzalez JB, Lloret CA, et al. Approximation to a cost-effectiveness analysis of treatment with G-CSF in non-solid tumours [in Spanish]. Farm Clin 1994 Mar; 11 (124-126, 131-134): 122
48. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy; results of a randomised trial [Abstract no. 1510]. Proc Am Soc Clin Oncol 1993; 12: 437
49. Stross P, Bunch C, Drugs in focus: 13. Colony-stimulating factors (filgrastim, lenograstim, molgramostim). Prescr J 1994; 34(3): 119-24
50. Livingston RB. Dose intensity and high dose therapy: two different concepts. Cancer 1994; 74: 1177-83
51. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995 Oct; 13 (10): 2483-9
52. Filgrastim - human granulocyte-colony stimulating factor. Drug Ther Bull 1995; 31: 33-6
53. Carlson JW, Fowler J, Saltzman AK, et al. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol [abstract]. Gynecol Oncol 1994 Jul; 54: 108
54. Sheridan WP, Fox RM. Haematopoietic growth factors and cancer therapy. Med J Aust 1993 Apr 19; 158: 514-6
55. Lazarus HM, Rowe JM. Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation. Blood Rev 1994 Sep; 8: 169-78
56. Dunlop DJ, Fitzsimons EJ, McMurray A, et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994 Nov; 70: 943-5
57. Bergstrom K, Herfinal ET. Issues in the rational clinical use of myeloid haematopoietic growth factors. Int Pharm J 1995 Mar-Apr; 9: 65-8
58. Burke KW. Dosage standardization for filgrastim [letter; see comments]. Am J Hosp Pharm 1992 Nov; 49: 2698
59. DiPiro CR. Filgrastim doses should not be standardized for pediatric patients [letter]. Am J Hosp Pharm 1993 Mar; 50: 447
60. Sinsabaugh DK, Freyer DR. Big cost savings from small filgrastim unit doses [letter]. Am J Hosp Pharm 1993 Jul; 50: 1363-4
61. Kaczmarski RS, Mufti GJ. Low-dose filgrastim therapy for chronic neutropenia [letter]. N Engl J Med 1993 Oct 21; 329: 1280-1
62. Yim JM, Matuszewski KA, Vermeulen Jr LC, et al. Surveillance of colony-stimulating factor use in US academic health centers. DICP 1995; 29: 475-81